Calquence (acalabrutinib)

Calquence (Acalabrutinib) is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of specific B-cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL). By selectively inhibiting BTK, a key enzyme involved in B-cell receptor signaling, Calquence disrupts pathways that support the growth, survival, and proliferation of cancerous B cells.

Administered orally, Calquence provides a targeted treatment approach designed to deliver effective disease control while maintaining a manageable safety profile. It may be used as monotherapy or in combination with other therapies, depending on the specific indication and treatment strategy determined by healthcare professionals.

Clinical studies have demonstrated that Calquence can significantly improve progression-free survival and achieve durable responses in patients with both newly diagnosed and previously treated hematologic malignancies. Its high selectivity for BTK helps provide effective inhibition of cancer cell signaling while minimizing off-target effects, making it an important option in modern blood cancer treatment.

As a next-generation BTK inhibitor, Calquence represents a major advancement in precision hematology by offering targeted therapy tailored to the biological mechanisms that drive B-cell cancers. Its proven efficacy, oral administration, and expanding clinical applications continue to make it a valuable treatment option for healthcare providers seeking innovative solutions for patients with hematologic malignancies.